The Internet of Medical Things(IoMT) has powerful cloud computing ability and efficient data collection ability, which can improve the accuracy and convenience of medical work. As most communications are over open networks, data should encrypted before uploading to ensure the confidentiality of sensitive user data. Searching for encrypted data has become a challenging problem. Public key Encryption with Keyword Search (PEKS) supports the search of encrypted data and provides data privacy protection. PEKS has become a trendy technology, but PEKS still has the following problems: 1. The cloud server, as a semi-honest but curious third party, is likely to return some wrong search results to save computing and bandwidth resources. 2. The single keyword search inevitably produces irrelevant results, wasting computing and bandwidth resources. 3. Most PEKS schemes use bilinear pairing, so the computational efficiency is relatively low. 4. PEKS schemes based on Public Key Infrastructure (PKI) or identity-based cryptography inevitably face problems with certificate management or key escrow. 5. Most PEKS schemes face serious security threats such as Keyword Guessing Attacks (KGA) and File Injection Attacks (FIA). To solve the above problems, we propose a new certificateless verifiable bilinear pair-free conjunctive keyword search encryption scheme(CLVPFCKS) for IoMT using multi-signature.

Lung cancer is the most common cause of cancer deaths worldwide, and lung adenocarcinoma (LUAD) is the most common histological subtype. However, the prognostic and predictive outcomes differ because of the heterogeneity of programmed cell death. The purpose of this work is to investigate and develop a cuproptosis-associated lncRNA-based LUAD prediction marker. We firstly performed bioinformatic analysis of the Cuprotosis database and The Cancer Genome Atlas (TCGA) database to obtain 19 cuprotosis-related gene datasets and transcriptional data for LUAD. Univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analysis were utilized to construct cuproptosis-associated lncRNA modes. LUAD patients were thus classified into high-risk and low-risk categories based on prognostic risk values, with a median of It acted as a boundary. Risk models were evaluated and validated using Kaplan-Meier analysis, principal component analysis (PCA), gene set enrichment analysis (GSEA) and nomograms. Utilizing the TCGA-LUAD dataset, we identified seven predicted cuproptosis-associated lncRNAs in tumor microenvironment to create the risk model. 95.54% (214/224) of high-risk category tumor samples included cuproptosis-associated gene alterations, compared to 85.65% (203/237) of low-risk category tumor samples, with TP53 accounting for the bulk of occurrences. According to these findings, risk value was superior to other clinical variables and tumor mutation burden as a predictor of 1-, 3-, and 5-year overall survival (OS). The predictive validity of the cuproptosis-associated lncRNA-based risk model for LUAD is high, and this may have implications for how lung cancer patients are treated individually.